gadobenate dimeglumine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4471	127000-20-8

Description:

Molecule	Description
Synonyms: multihance gadobenate dimeglumine	Molecular weight: 1058.16 Formula: C36H62GdN5O21 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

multihance
gadobenate dimeglumine

Molecular weight: 1058.16
Formula: C36H62GdN5O21
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 23, 2004	FDA	BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	575.56	51.85	120	5037	4436	63479429
Hypersensitivity	348.01	51.85	242	4915	292443	63191422
Contrast media reaction	310.25	51.85	57	5100	1068	63482797
Urticaria	289.82	51.85	175	4982	165627	63318238
Skin hypertrophy	258.26	51.85	59	5098	3332	63480533
Anaphylactic reaction	256.35	51.85	119	5038	65981	63417884
Skin induration	228.99	51.85	53	5104	3170	63480695
Anaphylactoid reaction	205.94	51.85	50	5107	3673	63480192
Skin tightness	203.58	51.85	51	5106	4265	63479600
Sneezing	171.42	51.85	62	5095	18156	63465709
Vomiting	157.95	51.85	209	4948	559408	62924457
Pruritus	147.52	51.85	163	4994	361290	63122575
Skin fibrosis	145.32	51.85	29	5128	851	63483014
Erythema	142.31	51.85	116	5041	175635	63308230
Nausea	128.79	51.85	239	4918	854232	62629633
Fibrosis	127.60	51.85	35	5122	4157	63479708
Throat tightness	96.83	51.85	45	5112	24842	63459023
Gadolinium deposition disease	90.50	51.85	14	5143	85	63483780
Throat irritation	87.42	51.85	48	5109	37599	63446266
Feeling hot	84.53	51.85	52	5105	50302	63433563
Dyspnoea	80.91	51.85	170	4987	661143	62822722
Skin hyperpigmentation	78.29	51.85	26	5131	5895	63477970
Joint contracture	74.47	51.85	19	5138	1705	63482160
Anaphylactic shock	71.56	51.85	36	5121	23597	63460268
Emotional distress	71.45	51.85	40	5117	32509	63451356
Foaming at mouth	71.33	51.85	17	5140	1151	63482714
Peau d'orange	70.74	51.85	12	5145	138	63483727
Scar	69.85	51.85	30	5127	13752	63470113
Contrast media allergy	63.68	51.85	18	5139	2383	63481482
Anhedonia	59.29	51.85	25	5132	10949	63472916
Drug ineffective	58.55	51.85	8	5149	1044757	62439108
Joint range of motion decreased	58.28	51.85	35	5122	32393	63451472
Skin discolouration	58.26	51.85	37	5120	37791	63446074

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	396.58	60.55	88	3087	3917	34949839
Hypersensitivity	291.36	60.55	131	3044	60904	34892852
Vomiting	177.46	60.55	159	3016	247462	34706294
Anaphylactic reaction	175.12	60.55	76	3099	32225	34921531
Urticaria	174.11	60.55	93	3082	62284	34891472
Skin induration	162.70	60.55	38	3137	2113	34951643
Nausea	161.06	60.55	174	3001	339734	34614022
Skin hypertrophy	160.21	60.55	39	3136	2590	34951166
Sneezing	155.93	60.55	44	3131	5198	34948558
Skin tightness	150.53	60.55	36	3139	2217	34951539
Anaphylactoid reaction	149.40	60.55	36	3139	2289	34951467
Contrast media reaction	145.89	60.55	30	3145	916	34952840
Joint contracture	108.86	60.55	27	3148	1934	34951822
Fibrosis	97.22	60.55	26	3149	2510	34951246
Joint range of motion decreased	92.82	60.55	32	3143	7280	34946476
Skin fibrosis	92.41	60.55	21	3154	1031	34952725
Scar	87.20	60.55	29	3146	5915	34947841
Anaphylactic shock	84.56	60.55	37	3138	15904	34937852
Pruritus	77.78	60.55	79	3096	141902	34811854
Extremity contracture	75.94	60.55	17	3158	779	34952977
Deformity	74.13	60.55	19	3156	1553	34952203

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	595.71	61.38	131	6570	6029	79731658
Hypersensitivity	554.13	61.38	316	6385	261923	79475764
Anaphylactic reaction	403.03	61.38	177	6524	83566	79654121
Urticaria	362.81	61.38	213	6488	184988	79552699
Contrast media reaction	356.38	61.38	71	6630	1999	79735688
Skin hypertrophy	320.98	61.38	76	6625	4852	79732835
Anaphylactoid reaction	318.90	61.38	77	6624	5345	79732342
Skin induration	280.21	61.38	67	6634	4458	79733229
Skin tightness	271.94	61.38	68	6633	5454	79732233
Sneezing	263.94	61.38	88	6613	19595	79718092
Vomiting	257.45	61.38	296	6405	665532	79072155
Nausea	229.80	61.38	336	6365	956860	78780827
Pruritus	201.98	61.38	204	6497	394444	79343243
Skin fibrosis	178.56	61.38	38	6663	1486	79736201
Erythema	157.19	61.38	138	6563	223152	79514535
Anaphylactic shock	140.79	61.38	66	6635	35930	79701757
Fibrosis	140.41	61.38	40	6661	5269	79732418
Joint contracture	128.81	61.38	32	6669	2492	79735195
Gadolinium deposition disease	108.38	61.38	17	6684	110	79737577
Scar	106.12	61.38	42	6659	15154	79722533
Joint range of motion decreased	100.04	61.38	51	6650	33231	79704456
Throat tightness	99.41	61.38	48	6653	27859	79709828
Skin hyperpigmentation	99.19	61.38	33	6668	7270	79730417
Throat irritation	87.42	61.38	50	6651	40896	79696791
Peau d'orange	85.06	61.38	16	6685	329	79737358
Contrast media allergy	85.05	61.38	23	6678	2499	79735188
Feeling hot	84.29	61.38	56	6645	59678	79678009
Contrast media deposition	81.50	61.38	13	6688	95	79737592
Dyspnoea	80.69	61.38	203	6498	856822	78880865
Emotional distress	70.11	61.38	43	6658	39926	79697761
Skin discolouration	69.07	61.38	43	6658	40991	79696696
Anhedonia	66.61	61.38	30	6671	14868	79722819
Burning sensation	64.07	61.38	47	6654	58585	79679102
Retching	62.05	61.38	30	6671	17437	79720250

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4032768	VUID
N0000188993	NUI
4032768	VANDF
CHEMBL1200571	ChEMBL_ID
C064572	MESH_SUPPLEMENTAL_RECORD_UI
3Q6PPC19PO	UNII
68173	RXNORM
19178	MMSL
64278	MMSL
64293	MMSL
d05428	MMSL
007717	NDDF
414308003	SNOMEDCT_US
C0209453	UMLSCUI
197281	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MultiHance	HUMAN PRESCRIPTION DRUG LABEL	1	0270-5164	INJECTION, SOLUTION	529 mg	INTRAVENOUS	NDA	28 sections
MultiHance	HUMAN PRESCRIPTION DRUG LABEL	1	0270-5264	INJECTION, SOLUTION	529 mg	INTRAVENOUS	NDA	27 sections